atenolol has been researched along with Pancreatic Neoplasms in 1 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The survival rate of patients with pancreatic cancer is low; therefore, continuous discovery and development of novel pancreatic cancer drugs are required." | 1.56 | Functional network analysis reveals potential repurposing of β-blocker atenolol for pancreatic cancer therapy. ( Hermawan, A; Putri, H; Utomo, RY, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hermawan, A | 1 |
| Putri, H | 1 |
| Utomo, RY | 1 |
1 other study available for atenolol and Pancreatic Neoplasms
| Article | Year |
|---|---|
Functional network analysis reveals potential repurposing of β-blocker atenolol for pancreatic cancer therapy.
Topics: Atenolol; Databases, Genetic; Drug Repositioning; Gene Expression Regulation, Neoplastic; Humans; Ka | 2020 |